We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Atlas Arteria is an infrastructure operations business based in Australia. Atlas Arteria shares (ALX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Atlas Arteria has a trailing 12-month revenue of around $100.7 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Atlas Arteria
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Atlas Arteria. Find the share by name or ticker symbol: ALX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atlas Arteria reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Atlas Arteria. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Our top pick for
US stocks

Our top pick for
Best Overall Broker

Our top pick for
Best low-cost broker

What's in this guide?
Atlas Arteria stock price (ASX:ALX)
Use our graph to track the performance of ALX stocks over time.Atlas Arteria shares at a glance
52-week range | $5.5075 - $7.03 |
---|---|
50-day moving average | $6.6592 |
200-day moving average | $6.5778 |
Target price | $6.85 |
PE ratio | 35.7592 |
Dividend yield | $0 (5.56%) |
Earnings per share (TTM) | $0.191 |
Compare share trading platforms
Is it a good time to buy Atlas Arteria stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Atlas Arteria price performance over time
Historical closes compared with the last close of A$6.85
1 week (2022-05-09) | 0.29% |
---|---|
1 month (2022-04-14) | 3.16% |
3 months (2022-02-16) | 2.24% |
6 months (2021-11-16) | 5.55% |
1 year (2021-05-14) | 10.13% |
---|---|
2 years (2020-05-15) | 14.93% |
3 years (2019-05-16) | -3.90% |
5 years (2017-05-16) | 24.58% |
Is Atlas Arteria under- or over-valued?
Valuing Atlas Arteria stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atlas Arteria's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atlas Arteria's P/E ratio
Atlas Arteria's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Atlas Arteria shares trade at around 36x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Atlas Arteria's EBITDA
Atlas Arteria's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $36.7 million (£0.0 million).
The EBITDA is a measure of a Atlas Arteria's overall financial performance and is widely used to measure a its profitability.
Atlas Arteria financials
Revenue TTM | $100.7 million |
---|---|
Gross profit TTM | $368.7 million |
Return on assets TTM | -0.29% |
Return on equity TTM | 4.59% |
Profit margin | 182.02% |
Book value | 3.647 |
Market capitalisation | $6.6 billion |
TTM: trailing 12 months
Atlas Arteria share dividends
Dividend payout ratio: 2% of net profits
Recently Atlas Arteria has paid out, on average, around 2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.56% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Atlas Arteria shareholders could enjoy a 5.56% return on their shares, in the form of dividend payments. In Atlas Arteria's case, that would currently equate to about A$0 per share.
While Atlas Arteria's payout ratio might seem low, this can signify that Atlas Arteria is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 21 March 2022 (the "ex-dividend date").
Atlas Arteria share price volatility
Over the last 12 months, Atlas Arteria's shares have ranged in value from as little as $5.5075 up to $7.03. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Atlas Arteria's is 0.8958. This would suggest that Atlas Arteria's shares are less volatile than average (for this exchange).
Atlas Arteria overview
Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in 22-kilometer toll road investors partnership II (TRIP II), the concessionaire for Dulles Greenway toll road located in Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.
Atlas Arteria in the news
Frequently asked questions
More guides on Finder
-
How to invest in the Regener8 Resources IPO
Everything we know about the Regener8 Resources IPO, plus information on how to buy in.
-
Cosmos: Cosmos Purpose Bitcoin Access ETF
While crypto ETFs remain a relatively new concept, here is how you can invest in one of the first physically back Bitcoin ETFs.
-
ETF Securities: The ETFS 21Shares Ethereum ETF (EETH)
Here is your how to guide on buying the first Ethereum backed ETF in Australia.
-
How to invest in the Southern Palladium Limited IPO
Everything we know about the Southern Palladium Limited IPO, plus information on how to buy in.
-
How to invest in the Coolabah Metals IPO
Everything we know about the Coolabah Metals IPO, plus information on how to buy in.
-
How to buy Firetail Resources (FTL) shares
Steps to owning and managing Firetail Resources shares.
-
What are hedged and unhedged ETFs and which is better for you?
Considering buying a hedged or unhedged ETF? Here is what you need to know prior to investing.
-
How to buy Gran Tierra Energy (GTE) shares in Australia
Steps to owning and managing Gran Tierra Energy shares from Australia.
-
What is copy trading and is it right for you?
Copy trading is a strategy that allows you to follow other traders. This guide will help you understand what it is and if its right for you.
Ask an Expert